---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-237900"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2022-09-02T23:59:59+00:00"
generated_at: "2026-06-23T16:37:01.826119+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silverback terminates President/CSO and CFO; appoints interim CFO ahead of merger

## Summary
- Terminated Valerie Odegard (President/CSO) and Jonathan Piazza (CFO), effective Sept 2, 2022, to extend cash runway.
- Odegard and Piazza entered consulting agreements at $350/hour (max 20 hrs/wk) through merger close or Nov 30, 2022.
- Equity awards continue vesting during consulting period; options remain exercisable.
- Russ Hawkinson appointed Interim CFO; he also serves as SVP Finance and principal accounting officer.

## SEC filing metadata
- accession: 0001193125-22-237900
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2022-09-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/d352338d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-237900
- JSON: https://secwatch.observer/filing/0001193125-22-237900.json
- Plain text: https://secwatch.observer/filing/0001193125-22-237900.txt

## Key facts
- Executive change
  Valerie Odegard was terminated as President and Chief Scientific Officer at ARS Pharmaceuticals, Inc..
  - Action: terminated
  - Role: President and Chief Scientific Officer
  source text: On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm
- Executive change
  Russ Hawkinson was appointed as Interim Chief Financial Officer at ARS Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: Effective as of the Transition Date, Russ Hawkinson has been appointed to serve as Silverback’s Interim Chief Financial Officer and principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm
- Executive change
  Jonathan Piazza was terminated as Chief Financial Officer at ARS Pharmaceuticals, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522237900/0001193125-22-237900-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.